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ABSTRACT
Introduction: The number of drug shortages in
the United States has increased in recent years.
While some literature exists on factors that
contribute to antimicrobial shortages, the need
remains to accurately gage the level of patient
harm incurred as a result of realized
antimicrobial shortages. Furthermore, current
methods of reporting adverse drug events are
known to under-report instances of patient
harm. We sought to develop an ongoing and
accurate method of reporting patient harm due
to antimicrobial shortages, which was
convenient, anonymous, and allowed
clinicians to estimate the causality due to a
shortage.
Methods: We distributed a public
SurveyMonkey (SurveyMonkey, Palo Alto,
CA, USA) link to gather information regarding
institution (for de-duplicating purposes),
patient age, sex, antimicrobial product on
shortage, type of infection requiring treatment
or prophylaxis, adverse event, and patient
outcome.
Results: To date complete data were reported
on four patients being treated for infections
that included Stenotrophomonas maltophilia
bacteremia, Pneumocystis jirovecii pneumonia,
neonatal sepsis of unknown etiology, and
cytomegalovirus colitis. Antimicrobials that
were unavailable to patients included
sulfamethoxazole–trimethoprim, gentamicin,
and foscarnet. Two adverse events (a delay in
treatment and an inability to treat with other
antimicrobials due to resistance) were
attributed with probable causality due to a
shortage, while the remaining adverse events
(death and an inability to tolerate high oral
doses) were attributed to have unlikely and
possible causalities due to a shortage,
respectively.
Conclusion: These methods encourage reports
of antimicrobial shortage harms.
Electronic supplementary material The online
version of this article (doi:10.1007/s40121-014-0040-z)
contains supplementary material, which is available to
authorized users.
M. M. McLaughlin  E. Skoglund  Z. Pentoney 
M. H. Scheetz (&)
Midwestern University, Chicago College of
Pharmacy, Downers Grove, IL, USA
e-mail: mscheetz@nmh.org
M. M. McLaughlin  M. H. Scheetz
Department of Pharmacy, Northwestern Memorial
Hospital, Chicago, IL, USA
Infect Dis Ther (2014) 3:349–355
DOI 10.1007/s40121-014-0040-z
Keywords: Adverse events; Antimicrobials;
Drug reporting; Drug shortages; Infectious
diseases; Patient outcomes; Survey
INTRODUCTION
Drug shortages are a persistent and rapidly
growing problem in the United States. The
annual frequency of drug shortages increased
200% from 2006 to 2010 [1]. Furthermore, in
2012 the Food and Drug Administration (FDA)
reported a record number of 251 drugs on
shortage [2]. The increasing problem of drug
shortages has the potential to adversely affect
patient care, delay medical procedures, result in
medication errors, and burden the health care
system with additional costs [3–5]. Drugs on
shortage may be irreplaceable life-saving
therapies. When these medications are
unavailable, it may lead to significant patient
harm when clinicians must resort to second- or
third-line agents that may have inferior or less
evidence for use. This is especially true for
shortages of often non-interchangeable,
curative therapies such as antimicrobials and
oncologic agents, which comprise the majority
of shortages [1]. A 2013 survey of infectious
disease physicians found that 78% (n = 489) of
respondents had to modify their choices of
antimicrobial therapy because of a drug
shortage in the previous 2 years [6]. Poor
patient outcomes due to a shortage were
reported by 55% (n = 345) of responding
physicians who reported having to use
alternative agents which were less effective,
more toxic, or more costly. The growing
magnitude of drug shortages and the risk of
patient harm they pose have gained much
attention from the government, media, and
researchers as strategies are developed to
mitigate their effects.
While progress has been made on
quantifying the magnitude and causes of drug
shortages, a lack of data exists on the causality
of shortages on patient outcomes as well as the
development of a system for reporting and
monitoring patient harm on a real-time basis.
There remains a need for appropriate tracking of
the relationship between drug shortages and
patient outcomes in the long term [1, 4].
Specifically, the need remains for a system
where clinicians can report specific instances
of patient harm they believe to be due to a drug
shortage.
Traditionally, adverse event reporting is
managed through the Adverse Events Reporting
System (AERS) of the FDA; however, AERS is
known to under-represent actual events due to
infrequent clinician reporting [7]. Furthermore,
drug shortages that lead to patient harm may not
be recognized as adverse events. We have
suggested that a novel method for maximizing
the reporting of adverse events due to drug
shortages would be simple, anonymous, use
standardized terminology for easy tabulation,
and have a mechanism for attributing causality
of the adverse event to a drug shortage [1, 4]. We
focused on shortages of antimicrobial drugs as
they are often non-interchangeable, curative,
and represent a large portion of overall shortages,
thus making them particularly sensitive to
shortages that result in patient harm. We
hypothesized that a novel method for reporting
patient harm due to antimicrobial shortages
would aid in anonymous and convenient
reporting of these cases of patient harm.
METHODS
Clinicians were asked anonymously to report
occurrences of patient harm related to
antimicrobial drug shortages through an
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online survey (SurveyMonkey; SurveyMonkey,
Palo Alto, CA, USA [8]) consisting of 11
questions (Table 1). The survey was distributed
through an editorial in Pharmacotherapy [4], a
letter in the American Journal of Health-System
Pharmacy [1], and through the American
College of Clinical Pharmacy (ACCP)
Infectious Diseases Practice and Research
Network (ID PRN) email listserv. Reports from
the survey were tabulated from August 2012
through October 2013, and three reminder
emails were sent to the ACCP ID PRN during
this timeframe. This study was approved as
exempt by the Midwestern University
Institutional Review Board.
Respondents were surveyed regarding:
institution (for de-duplication purposes),
patient age (if \90 years old), sex,
antimicrobial on shortage, type of infection
requiring treatment or prophylaxis, adverse
event, and patient outcome. Criteria for
causality attribution were obtained from the
Common Terminology Criteria for Adverse
Events (CTCAE) of the National Cancer
Institute [9]. Using these criteria, the reporter
assessed the relationship between the adverse
event and the antimicrobial shortage as
unrelated (clearly not related), unlikely
(doubtfully related), possible (may be related),
or probable (likely related). The severity of the
adverse event was also assessed using
standardized AERS criteria, modified for the
setting of infectious diseases [10]. Using these
criteria, the reporter classified the severity of the
adverse event according to the following
terminology: death, treatment failure or
development of antibiotic resistance,
readmission due to treatment failure, increased
length of hospital stay, patient transfer to an
institution with a supply of antimicrobial, delay
of active therapy, canceled care, or other.
Survey responses were tabulated and
descriptively analyzed as a case series.
RESULTS
Overall, there were seven de-duplicated reports
of adverse events related to antimicrobial
shortages. Four reports were complete and
three were incomplete. The incomplete reports
did not provide the level of causality due to a
shortage but did report an instance of patient
harm. The four complete reports were from
unique institutions. All institutions were in
urban settings with 500–740 beds (n = 3) or
100–249 beds (n = 1).
For the complete reports, the antimicrobials
on shortage included sulfamethoxazole–
trimethoprim, gentamicin, and foscarnet
(Table 2). The infections for which these
patients were being treated or receiving
prophylaxis included Stenotrophomonas
maltophilia bacteremia, Pneumocystis jirovecii
pneumonia, neonatal sepsis of unknown
etiology, and cytomegalovirus colitis. Final
patient outcomes included death, delay of
therapy, readmission, and limited access to
treatment. Two adverse events (a delay in
treatment and an inability to treat with other
antimicrobials due to resistance) were attributed
to have probable causality due to a shortage,
while the remaining adverse events (death and
an inability to tolerate high oral doses) were
attributed to have unlikely and possible
causalities due to a shortage, respectively. The
antimicrobials on shortage in the incomplete
reports included three cases of a shortage of
sulfamethoxazole–trimethoprim. The infections
for which these patients were being treated or
receiving prophylaxis were P. jirovecii
pneumonia and Stenotrophomonas spp.
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DISCUSSION
Our study found specific instances of patient harm
due to antimicrobial shortages. The methodology
demonstrated in this study illustrates a successful
system capable of capturing real-time instances of
patient harm and attributing the causality of that
harm toantimicrobial shortages. By maintaining a
database where the specialists most likely to
manage shortages can continuously report
Table 1 Survey questions
1 Please list the full name of your institution (for de-duplicating purposes)
2 How many inpatient beds does your institution currently have?
3 Which of the following best describes the location of your institution?
Urban, Suburban, Rural
4 Was the patient’s age under 90 years old? If yes, please list the patient’s age
5 Sex: male or female
6 Which antimicrobial was unavailable for your patient?
7 Please list the infection for which treatment or prophylaxis was needed
8 What adverse event did your patient experience?
9 Please attribute the causality of the shortage to the adverse event that occurred in your patient
Unrelated: the adverse event is clearly not related to the shortage
Unlikely: the adverse event is doubtfully related to the shortage
Possible: the adverse event may be related to the shortage
Probable: the adverse event is likely related to the shortage







11 What was the ﬁnal patient outcome? Please check all that apply
Death
Treatment failure/development of resistance
Readmission due to treatment failure
Increased length of hospitalization
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instances of patient harm anonymously and
conveniently, we believe our methodology offers
an ability to capture harmful effects of
antimicrobial drug shortages on patient
outcomes. Clinicians wishing to report on future
harms due to antimicrobial shortages can do so at:
http://www.surveymonkey.com/s/antimicrobial
shortages.
The instances of patient harm reported in
this study further underline the harmful effects
of drug shortages reported elsewhere in the
literature. These effects include utilization of
less effective or more toxic alternative
medications, medical errors, delays in
procedures, and higher healthcare costs [3–5].
For example, two of the drugs on shortage
reported in our survey are first-line agents for
their respective indications (i.e.,
sulfamethoxazole–trimethoprim for P. jirovecii
pneumonia prophylaxis, and foscarnet for
cytomegalovirus colitis). It is worth noting
that two of the three antimicrobials reported
to be on shortage in our survey required
clinicians to follow special instructions to
obtain a supply. For example,
sulfamethoxazole–trimethoprim was available
through drop shipments from the
manufacturer only after the need for therapy
was documented to the manufacturer.
Foscarnet was available from the United
Kingdom via importation from a single
manufacturer. As there may be significant time
lags associated with obtaining such products,
special measures are required to ensure ready
access to the product at the time of need.
Of further note, the number of full-time
equivalents allocated to shortage management
has increased in many healthcare institutions;
this has not seemed to curb the inability of
some institutions to procure drugs on shortage
[11]. One potential solution may be increased
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and how best to mitigate their harmful effects,
which antimicrobial stewardship programs
could potentially provide [12].
This survey methodology, a quick and
anonymous online survey, offers an
advantageous alternative over conventional
surveys which may only provide a snapshot of
the incidence of patient harm and not specific
patient characteristics [4]. The benefits of the
FDA AERS system include that it is a publically
available system for reporting adverse events
and it provides a form that prompts reporters
for pertinent information. However, due to
issues such as prescriber disinclination to
report for fear of identification and litigation,
lack of time to submit reports, and lack of
knowledge of the reporting structure, most
adverse drug events are never reported. It has
been estimated that under-reporting exists over
90% of the time [13]. Specifically in regards to
the AERS system, an original study found that
only 57% of prescribers were aware of AERS,
likely leading to reporting rates ranging from
1% to 5% [14]. We have written about the need
for standardization of assessing the impact of
antimicrobial shortages on patient outcomes
and suggested that the traditional method of
reporting adverse events is likely under-
reporting the true impact due to the time
required for submissions, the complexity of
the system, and the personally identifying
nature of the report [1, 4]. A 2009 review of
the determinants of under-reporting of adverse
events found under-reporting to be influenced
in part by a lack of suitable means to report the
event in 75% (n = 45) of all studies, and that the
available system was considered to be too
bureaucratic or not easy enough in 25%
(n = 45) of all studies [7]. The methodology
presented here may also be useful in assessing
patient harm due to shortages in other drug
classes.
Limitations to our survey must be
considered. Reports may have been limited as
respondents may have not wished to disclose
medication errors or adverse events which
occurred at their institutions. Accuracy of self-
reporting is an inherent liability to which all
surveys, including the FDA AERS database, are
subject. The results from our survey were driven
by large institutions in urban settings; however,
results from elsewhere in the literature clearly
demonstrate that institutions of all sizes and
settings are affected by shortages [6, 11]. Despite
these limitations, the results of this survey
provide valuable information regarding patient
harm due to antimicrobial drug shortages.
CONCLUSIONS
Our study demonstrated a novel method for
encouraging providers to report patient harm
due to antimicrobial shortages. This method is
standardized, anonymous, convenient, and
capable of de-duplicating responses. This pilot
study has revealed unique instances of patient
harm with assessed causality attributed to
antimicrobial shortages. Such studies may help
gage the true impact of shortages and may help
guide policies aimed at allocating appropriate
resources to control and prevent patient harm
caused by future shortages.
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